Keros Therapeutics (KROS) said Monday that it has agreed to a deal with Massachusetts General Hospital for the design of a phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis.
The collaboration is part of an initiative to speed up development of new therapies for the illness using genetic and biofluid markers, the company said.
Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that leads to muscle weakness and loss of physical control.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments